Genetically-engineered mouse models (Pdx-1-Cre/KrasG12D/Ink4a/Arflox/lox and Pdx-1-Cre; LSL-KrasGD12; LSL-Trp53R172H mice), which develop pancreatic tumors [44, 45], could not be used since the tested tumors showed no reactivity to mAbJ28. This evidence concerns the gene CDKN2A and pancreatic neoplasm.